GO:0016250 N-sulfoglucosamine sulfohydrolase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016250 describes the molecular function N-sulfoglucosamine sulfohydrolase activity, which catalyzes the hydrolysis of N-sulfo-D-glucosamine to D-glucosamine and sulfate.
• This activity is essential for the stepwise degradation of heparan sulfate; its deficiency causes the lysosomal storage disorder mucopolysaccharidosis type IIIA (Sanfilippo syndrome A).
• The enzyme responsible, sulfamidase (SGSH), is a lysosomal hydrolase whose three-dimensional structure has been solved, revealing how missense mutations impair catalysis.
• Measuring SGSH activity in brain homogenates requires careful control of pH, substrate concentration, and other variables to ensure reproducible results.
• Recombinant sulfamidase (SOBI003) and AAV9-mediated gene delivery are being explored as therapeutic strategies to restore enzyme activity in the central nervous system.
• Fluorogenic substrates and immune-deficient mouse models have accelerated preclinical research on MPS IIIA and the evaluation of novel therapies.
Description
N-sulfoglucosamine sulfohydrolase activity (GO:0016250) is a molecular function that removes sulfate groups from N-sulfo-D-glucosamine residues during the lysosomal degradation of heparan sulfate. This activity is indispensable for the complete breakdown of glycosaminoglycans, and its loss leads to the accumulation of partially degraded heparan sulfate in lysosomes, a hallmark of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome A). Researchers study this activity to understand lysosomal storage disorders, to develop diagnostic assays, and to evaluate therapeutic approaches such as enzyme replacement and gene therapy. The enzyme responsible, sulfamidase (encoded by the SGSH gene), is a target for structure-function studies and for the design of small-molecule chaperones or substrate analogs. Because the activity is central to heparan sulfate catabolism, its measurement and manipulation are relevant to neurobiology, pediatrics, and drug development.
N-sulfoglucosamine sulfohydrolase activity At A Glance
| GO ID | GO:0016250 |
|---|---|
| GO term | N-sulfoglucosamine sulfohydrolase activity |
| Ontology | molecular_function |
| Synonym | heparin sulfamidase activity; N-sulfo-D-glucosamine sulfohydrolase activity; sulphamidase activity; sulfoglucosamine sulfamidase activity |
| Major function | Catalyzes the hydrolysis of N-sulfo-D-glucosamine to D-glucosamine and sulfate, a key step in heparan sulfate degradation |
| Reaction | N-sulfo-D-glucosamine + H2O = D-glucosamine + sulfate |
| Cellular location | Lysosome (as part of the heparan sulfate degradation pathway) |
| Associated gene | SGSH (sulfamidase) |
| Related disease | Mucopolysaccharidosis type IIIA (Sanfilippo syndrome A) |
What Is GO:0016250?
According to the Gene Ontology, N-sulfoglucosamine sulfohydrolase activity (GO:0016250) is defined as the catalysis of the reaction: N-sulfo-D-glucosamine + H2O = D-glucosamine + sulfate. In other words, it is an enzyme activity that cleaves the sulfate group from N-sulfo-D-glucosamine, releasing free sulfate and D-glucosamine. This activity is also known by synonyms such as heparin sulfamidase activity, N-sulfo-D-glucosamine sulfohydrolase activity, and sulphamidase activity. It is a molecular function that contributes to the broader biological process of heparan sulfate proteoglycan catabolism.
Why Is N-sulfoglucosamine sulfohydrolase activity Important in Cell Biology?
N-sulfoglucosamine sulfohydrolase activity is critical for normal lysosomal turnover of heparan sulfate, and its deficiency causes the severe neurodegenerative disorder MPS IIIA. Understanding this activity at the molecular level informs diagnosis, prognosis, and the development of therapies aimed at restoring enzyme function in the brain. Moreover, accurate measurement of this activity is essential for preclinical and clinical studies, as highlighted by methodological work on fluorimetric assays.
• Deficiency of this activity leads to mucopolysaccharidosis type IIIA (Sanfilippo syndrome A), a progressive neurodegenerative disease.
• It is a key enzyme in heparan sulfate catabolism, and its dysfunction results in lysosomal accumulation of partially degraded glycosaminoglycans.
• Measuring its activity in brain tissue requires optimization of assay conditions, which is critical for reliable diagnosis and research.
• Recombinant human sulfamidase (SOBI003) has been tested in clinical trials for MPS IIIA, highlighting the therapeutic relevance of this activity.
• AAV9-mediated delivery of sulfamidase is a promising gene therapy approach for MPS IIIA.
• Fluorogenic substrates specific for this activity enable high-throughput screening and enzyme characterization.
• Immune-deficient mouse models of MPS IIIA facilitate long-term studies of enzyme replacement and gene therapy.
• Late-onset forms of MPS IIIA can present with atypical symptoms such as visual impairment, underscoring the clinical heterogeneity linked to this activity.
• Structural studies of sulfamidase provide a framework for understanding how mutations affect catalytic activity and for designing chaperones.
• Intracerebroventricular administration of the enzyme reduces markers of lysosomal dysfunction in MPS IIIA mice, demonstrating the importance of brain-targeted delivery.
What Happens During N-sulfoglucosamine sulfohydrolase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs onto a specific sugar molecule that has a sulfate group attached.
Sulfamidase (SGSH) recognizes N-sulfo-D-glucosamine residues within partially degraded heparan sulfate chains. Structural studies of sulfamidase have revealed the active site architecture that accommodates the sulfated sugar substrate. The enzyme binds the substrate in the lysosome, where it encounters heparan sulfate fragments generated by prior enzymatic steps.
Catalytic hydrolysis of the sulfate group
In simple terms: The enzyme cuts off the sulfate group from the sugar, releasing it as free sulfate.
The catalytic mechanism involves hydrolysis of the N-sulfate bond, yielding D-glucosamine and inorganic sulfate. This reaction is essential for the stepwise degradation of heparan sulfate, and its failure leads to the accumulation of N-sulfated oligosaccharides in lysosomes. The activity is measured in vitro using fluorogenic substrates that mimic the natural substrate.
Product release and downstream processing
In simple terms: After the sulfate is removed, the sugar is further broken down by other enzymes.
Following the removal of the sulfate group, the resulting D-glucosamine residue becomes a substrate for subsequent enzymes in the heparan sulfate degradation pathway. This sequential action ensures complete breakdown of glycosaminoglycans, and deficiency of sulfamidase blocks this process, causing lysosomal storage.
Assay and measurement of activity
In simple terms: Scientists measure how well the enzyme works by using special chemicals that glow when the sulfate is removed.
Fluorimetric assays using 4-methylumbelliferyl substrates are commonly used to measure SGSH activity in tissue homogenates. Variables such as pH, substrate concentration, and incubation time must be carefully controlled to obtain reliable results. Novel fluorogenic substrates have been synthesized to improve the sensitivity and specificity of MPS IIIA diagnosis.
Key Genes Involved in GO:0016250 N-sulfoglucosamine sulfohydrolase activity
The following genes and proteins are directly or indirectly associated with N-sulfoglucosamine sulfohydrolase activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SGSH | Encodes sulfamidase, the enzyme that catalyzes N-sulfoglucosamine sulfohydrolase activity | Mutations cause MPS IIIA; target for gene therapy and enzyme replacement |
| IDS | Encodes iduronate-2-sulfatase, involved in heparan sulfate degradation upstream of SGSH | Deficiency causes MPS II; used as a comparative model for lysosomal storage |
| HGSNAT | Encodes heparan-alpha-glucosaminide N-acetyltransferase, another enzyme in heparan sulfate catabolism | Deficiency causes MPS IIIC; helps delineate pathway specificity |
| NAGLU | Encodes alpha-N-acetylglucosaminidase, acts downstream of SGSH | Deficiency causes MPS IIIB; relevant for understanding substrate accumulation |
| GNS | Encodes N-acetylglucosamine-6-sulfatase, involved in heparan sulfate degradation | Deficiency causes MPS IIID; provides context for sulfatase family functions |
| GALNS | Encodes galactosamine-6-sulfatase, involved in keratan sulfate and chondroitin sulfate degradation | Deficiency causes MPS IVA; illustrates related sulfatase deficiencies |
| ARSB | Encodes arylsulfatase B, degrades dermatan sulfate and chondroitin sulfate | Deficiency causes MPS VI; highlights diversity of sulfatase disorders |
| SUMF1 | Encodes formylglycine-generating enzyme, required for activation of sulfatases including SGSH | Mutations cause multiple sulfatase deficiency; essential for SGSH function |
| GUSB | Encodes beta-glucuronidase, involved in glycosaminoglycan degradation | Deficiency causes MPS VII; used as a control in enzyme studies |
| CTSA | Encodes cathepsin A, a lysosomal protease that stabilizes several glycosidases | Deficiency causes galactosialidosis; may affect lysosomal enzyme stability |
| LAMP1 | Lysosomal-associated membrane protein 1, marker of lysosomes | Used to assess lysosomal enlargement in MPS IIIA models |
| LAMP2 | Lysosomal-associated membrane protein 2, marker of lysosomes | Used to evaluate lysosomal dysfunction in MPS IIIA |
| GFAP | Glial fibrillary acidic protein, marker of astrocyte activation | Elevated in MPS IIIA brain, indicating neuroinflammation |
| AIF1 | Allograft inflammatory factor 1 (Iba1), marker of microglial activation | Increased in MPS IIIA, reflecting neuroinflammation |
| BACE1 | Beta-secretase 1, involved in amyloid precursor protein processing | Altered in neurodegenerative models; may be affected in MPS IIIA |
| MAP2 | Microtubule-associated protein 2, neuronal marker | Used to assess neuronal integrity in MPS IIIA models |
| SYP | Synaptophysin, synaptic vesicle marker | Evaluated in MPS IIIA to assess synaptic density |
| MBP | Myelin basic protein, marker of myelination | Studied in MPS IIIA to detect white matter changes |
How Is N-sulfoglucosamine sulfohydrolase activity Regulated?
The activity of N-sulfoglucosamine sulfohydrolase is primarily regulated at the level of enzyme synthesis, lysosomal targeting, and post-translational modification. Sulfamidase, like other sulfatases, requires activation by the formylglycine-generating enzyme (SUMF1) to convert a conserved cysteine to formylglycine, which is essential for catalytic activity. Additionally, the enzyme's lysosomal localization is mediated by mannose-6-phosphate receptors, and its stability can be influenced by interactions with other lysosomal proteins. In disease states, the accumulation of substrate can lead to secondary changes in lysosomal function and cellular homeostasis. However, direct transcriptional or signaling regulation of SGSH in response to extracellular cues is not well characterized in the provided literature.
N-sulfoglucosamine sulfohydrolase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SGSH | Mucopolysaccharidosis type IIIA (Sanfilippo syndrome A) | Sgsh knockout mouse; patient-derived fibroblasts; AAV9-SGSH treated mice |
| SUMF1 | Multiple sulfatase deficiency | Sumf1 knockout mouse; cell lines expressing mutant SUMF1 |
| IDS | Mucopolysaccharidosis type II (Hunter syndrome) | Ids knockout mouse; enzyme activity assays |
| NAGLU | Mucopolysaccharidosis type IIIB (Sanfilippo syndrome B) | Naglu knockout mouse; fluorogenic substrate assays |
| HGSNAT | Mucopolysaccharidosis type IIIC (Sanfilippo syndrome C) | Hgsnat knockout mouse; lysosomal storage models |
Mucopolysaccharidosis type IIIA (Sanfilippo syndrome A)
MPS IIIA is an autosomal recessive lysosomal storage disorder caused by mutations in the SGSH gene, leading to deficient N-sulfoglucosamine sulfohydrolase activity. The disease is characterized by progressive neurodegeneration, cognitive decline, and behavioral abnormalities, with onset typically in early childhood. The accumulation of partially degraded heparan sulfate in the brain triggers neuroinflammation and lysosomal dysfunction, as evidenced by elevated markers such as LAMP1 and GFAP in mouse models. Late-onset forms can present with atypical features such as visual impairment, mimicking other syndromes.
Neuroinflammation and neurodegeneration
Deficiency of N-sulfoglucosamine sulfohydrolase activity leads to microglial and astrocytic activation, which contributes to the neurodegenerative phenotype of MPS IIIA. Studies in mouse models have shown increased expression of AIF1 and GFAP, indicating robust neuroinflammatory responses. Intracerebroventricular administration of the enzyme reduces these markers, suggesting that neuroinflammation is a direct consequence of lysosomal dysfunction.
Therapeutic approaches targeting the enzyme
Enzyme replacement therapy with chemically modified recombinant human sulfamidase (SOBI003) has been evaluated in MPS IIIA patients, with the aim of restoring enzyme activity in the central nervous system. Gene therapy using AAV9 vectors to deliver the SGSH gene is also under investigation, and biopotency assays are being developed to assess vector efficacy. These approaches highlight the clinical importance of restoring N-sulfoglucosamine sulfohydrolase activity.
From N-sulfoglucosamine sulfohydrolase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SGSH cause lysosomal storage and neuroinflammation? | Sgsh knockout mouse (constitutive or conditional) |
| Can a specific point mutation in SGSH alter enzyme activity? | Point-mutation knock-in mouse or patient-derived cells |
| Does restoring SGSH expression rescue disease phenotypes? | AAV9-mediated gene delivery in Sgsh knockout mice |
| How does sulfamidase interact with other lysosomal proteins? | Tagged knock-in of SGSH (e.g., FLAG or GFP) for co-immunoprecipitation |
| What is the effect of SGSH overexpression on heparan sulfate levels? | Transgenic overexpression of SGSH in wild-type or disease models |
| Can small molecules enhance mutant SGSH activity? | High-throughput screening using fluorogenic substrates and patient fibroblasts |
How to Study the N-sulfoglucosamine sulfohydrolase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorimetric enzyme assay | SGSH activity using fluorogenic substrate | Diagnosis of MPS IIIA; measuring enzyme activity in tissues |
| X-ray crystallography | Three-dimensional structure of sulfamidase | Understanding mutation effects; drug design |
| Immunohistochemistry | Lysosomal markers (LAMP1, LAMP2) and neuroinflammation markers (GFAP, AIF1) | Assessing disease pathology in mouse models |
| AAV9 biopotency assay | In vitro potency of AAV9-SGSH vector | Gene therapy development |
| Behavioral testing | Cognitive and motor function in MPS IIIA mice | Evaluating therapeutic efficacy |
| Mass spectrometry | Heparan sulfate disaccharide composition | Quantifying substrate accumulation |
| Western blot | Sulfamidase protein levels | Confirming expression after gene therapy |
| qPCR | SGSH mRNA levels | Assessing transcriptional regulation |
Enzyme activity assays
Fluorimetric assays using 4-methylumbelliferyl substrates are the gold standard for measuring N-sulfoglucosamine sulfohydrolase activity in tissue homogenates and cell lysates. These assays require optimization of pH, substrate concentration, and incubation time to ensure accuracy. Novel fluorogenic substrates with improved properties have been developed for MPS IIIA and IIIB.
Structural biology
X-ray crystallography and cryo-electron microscopy have been used to determine the structure of sulfamidase, providing insights into substrate binding and the molecular pathology of MPS IIIA mutations. These structural studies guide the design of chaperones and enzyme variants with enhanced stability.
Animal models and behavioral studies
Mouse models of MPS IIIA, including immune-deficient strains, are used to evaluate disease progression and therapeutic interventions. Behavioral tests, histopathology, and biochemical assays of lysosomal markers are commonly employed.
Gene therapy and vector characterization
AAV9 vectors expressing SGSH are tested for biopotency in vitro and in vivo, using enzyme activity assays and quantification of heparan sulfate storage. These studies are critical for advancing gene therapy to clinical trials.
How CRISPR Can Be Used to Study GO:0016250 N-sulfoglucosamine sulfohydrolase activity
Knockout
CRISPR-Cas9 knockout of SGSH in cell lines or mice recapitulates the biochemical hallmark of MPS IIIA: loss of N-sulfoglucosamine sulfohydrolase activity and accumulation of heparan sulfate. These models are essential for studying disease mechanisms and testing therapies.
Point Mutation
Introducing patient-specific missense mutations into the SGSH gene via CRISPR base editing or homology-directed repair allows researchers to dissect how individual mutations affect enzyme stability and catalytic activity. Such models can reveal genotype-phenotype correlations.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous SGSH locus enables real-time tracking of enzyme localization and interaction partners. This approach is valuable for understanding lysosomal trafficking.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of SGSH can be used to study the effects of increased enzyme activity on heparan sulfate metabolism and to evaluate the therapeutic potential of enzyme augmentation.
How EDITGENE Supports N-sulfoglucosamine sulfohydrolase activity Research
Researchers studying N-sulfoglucosamine sulfohydrolase activity-related genes often need to determine whether a candidate gene is causally involved in lysosomal storage, neuroinflammation, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous investigation of GO:0016250 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for N-sulfoglucosamine sulfohydrolase activity research.
Frequently Asked Questions About N-sulfoglucosamine sulfohydrolase activity
What is N-sulfoglucosamine sulfohydrolase activity?
It is an enzyme activity (GO:0016250) that catalyzes the hydrolysis of N-sulfo-D-glucosamine to D-glucosamine and sulfate, a key step in heparan sulfate degradation.
What gene encodes N-sulfoglucosamine sulfohydrolase?
The SGSH gene encodes sulfamidase, the enzyme responsible for this activity.
What diseases are associated with N-sulfoglucosamine sulfohydrolase deficiency?
Deficiency causes mucopolysaccharidosis type IIIA (Sanfilippo syndrome A), a progressive neurodegenerative disorder.
How is N-sulfoglucosamine sulfohydrolase activity measured?
It is typically measured using fluorimetric assays with 4-methylumbelliferyl substrates in tissue homogenates or cell lysates.
What are the symptoms of MPS IIIA?
Symptoms include developmental delay, behavioral problems, cognitive decline, and in late-onset forms, visual impairment.
Is there a treatment for MPS IIIA?
Enzyme replacement therapy with recombinant sulfamidase and gene therapy with AAV9-SGSH are under investigation.
What animal models are used to study N-sulfoglucosamine sulfohydrolase activity?
Sgsh knockout mice and immune-deficient mouse models of MPS IIIA are commonly used.
What is the structure of sulfamidase?
The crystal structure of sulfamidase has been solved, revealing the active site and how mutations cause MPS IIIA.
How does N-sulfoglucosamine sulfohydrolase relate to heparan sulfate?
It removes sulfate groups from N-sulfo-D-glucosamine residues during heparan sulfate degradation.
Can CRISPR be used to study N-sulfoglucosamine sulfohydrolase activity?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to study SGSH function and disease mechanisms.
Conclusion
N-sulfoglucosamine sulfohydrolase activity (GO:0016250) is a fundamental enzymatic function required for heparan sulfate catabolism, and its deficiency causes the devastating neurodegenerative disorder MPS IIIA. Research into this activity spans structural biology, assay development, animal models, and therapeutic innovation, including enzyme replacement and gene therapy. Continued investigation will deepen our understanding of lysosomal storage diseases and may yield new treatments for Sanfilippo syndrome.
References
- 1. Magat J et al.. 2022. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.. J Biol Chem 298(12):102625 PMID: 36306823
- 2. Whyte LS et al.. 2015. Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SGSH) activity measurement in brain homogenates.. Mol Genet Metab Rep 5:60-62 PMID: 28652977
- 3. De Falco A et al.. 2024. Late-onset mucopolysaccharidosis type IIIA mimicking Usher syndrome.. Am J Med Genet A 194(5):e63517 PMID: 38149346
- 4. Pollock K et al.. 2023. An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome).. Sci Rep 13(1):18439 PMID: 37891179
- 5. Sidhu NS et al.. 2014. Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA.. Acta Crystallogr D Biol Crystallogr 70(Pt 5):1321-35 PMID: 24816101
- 6. Pan Y et al.. 2025. Efficient synthesis of fluorogenic substrates for mucopolysaccharidosis (MPS) IIIA and IIIB via aromatic α-glycosylation with thioglycosyl donors.. Org Biomol Chem 23(26):6446-6455 PMID: 40528812
- 7. Adhikari P et al.. 2026. Assessing the biopotency of the rAAV9 vector In Vitro.. PLoS One 21(2):e0341451 PMID: 41746933
- 8. Harmatz P et al.. 2022. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study.. Mol Genet Metab 136(4):249-259 PMID: 35835061
